Welcome to our dedicated page for NovaBridge Biosciences SEC filings (Ticker: NBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NovaBridge Biosciences (NBP) SEC filings page on Stock Titan provides access to the company’s official disclosures as a foreign private issuer listed on Nasdaq. NovaBridge, formerly known as I-Mab, files reports such as Form 20-F and Form 6-K that describe its financial condition, risk factors, and operational progress as a global biotechnology platform company.
In these filings, NovaBridge outlines its business model, which combines business development and translational clinical development to advance a pipeline led by givastomig, ragistomig, uliledlimab, and VIS-101. Management’s discussion and analysis sections describe how the company allocates resources to oncology and ophthalmology programs, summarizes its collaborations with partners such as ABL Bio, and explains the structure of subsidiaries like Visara within its hub-and-spoke framework.
Investors reviewing NovaBridge’s SEC reports can examine clinical development disclosures for givastomig, including its positioning as a Claudin 18.2 x 4-1BB bispecific antibody in gastric and other gastrointestinal cancers, and for ragistomig as a PD-L1 x 4-1BB bispecific in solid tumors. Filings also discuss rights to uliledlimab outside Greater China and the VIS-101 license and assignment arrangements involving Visara and Everest Medicines.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as segment descriptions, collaboration agreements, share incentive plans, and subsequent events. Users can follow new 6-K submissions for interim updates, and consult annual filings for a more comprehensive view of NovaBridge’s strategy, risk profile, and pipeline.
By using this page, investors and researchers can monitor NovaBridge’s official SEC communications in real time, while AI-generated insights help interpret complex biotech and capital markets information contained in the original documents.
NovaBridge Biosciences reports that its Chief Executive Officer, Dr. Sean Fu, intends to purchase up to $100,000 of the company’s American depositary shares in open market transactions. These purchases began on January 22, 2026, and the company notes there is no guarantee regarding the exact number of ADSs that will be acquired or the time frame over which any purchases will occur.
The report also reiterates that statements about these planned purchases and the development, strategy, safety, efficacy and anticipated milestones for drug candidates such as givastomig, ragistomig, uliledlimab and VIS-101 are forward-looking and subject to significant risks. These risks include clinical outcomes, regulatory decisions, market conditions, intellectual property protection, third-party dependencies and the company’s ability to secure additional funding, as discussed in its prior SEC filings.
NovaBridge Biosciences reports that Dr. Sean Cao, its Chief Business Development Officer and Board member, intends to purchase up to $100,000 of the company’s American depositary shares in open market transactions. These purchases began on January 21, 2026, and there is no guarantee regarding the exact number of ADSs that will be bought or the time period over which they will occur.
The company also reiterates standard forward-looking statement language, highlighting that expectations about potential ADS purchases, its drug candidates, and anticipated clinical milestones involve risks and uncertainties, including market conditions, clinical results, regulatory decisions, intellectual property protection, reliance on third parties, and its need for additional funding.
NovaBridge Biosciences reports that its Executive Chairman, Fu Wei, plans to purchase up to $5,000,000 of the company’s American depositary shares in open market transactions through an entity he controls. The purchases began on January 15, 2026, but there is no assurance on how many ADSs will ultimately be bought or over what period, since execution depends on his decisions and market conditions.
NovaBridge Biosciences reported updated Phase 1b data for its bispecific antibody givastomig in first-line HER2-negative metastatic gastric cancer, given with nivolumab and mFOLFOX6 chemotherapy. Among efficacy-evaluable patients, overall response rates were 77% (20/26) at 8 mg/kg and 73% (19/26) at 12 mg/kg, with responses seen across a wide range of CLDN18.2 and PD-L1 expression levels. Median progression-free survival reached 16.9 months at 8 mg/kg, while the 12 mg/kg cohort is less mature, with strong six‑month PFS rates of 73% and 91% in the 8 mg/kg and 12 mg/kg groups, respectively.
The safety profile was generally comparable to standard first-line regimens, with common treatment-related effects such as fatigue, nausea, and neutropenia, and no Grade 5 events reported. Immune‑related gastritis occurred in about one‑third of patients, was mostly manageable, and was associated with better outcomes. Management positions givastomig as a potential best‑in‑class CLDN18.2 therapy in a gastric cancer market the company estimates at $12 billion by 2030 and plans to start a global randomized Phase 2 trial in Q1 2026.
NovaBridge Biosciences reports results for the nine months ended September 30, 2025, highlighting a much smaller loss and a stronger cash position as it refocuses on a global biotech platform model. The net loss from continuing operations narrowed to $15.5 million from $38.9 million a year earlier, as research and development spending fell to $7.2 million and administrative expenses declined to $14.1 million after the divestiture of Greater China operations and internal restructuring.
The company ended the period with $228.1 million in cash and cash equivalents and $0.2 million in short-term investments, helped by a July underwritten offering that raised approximately $61.2 million in net proceeds. NovaBridge is pursuing a dual primary listing and IPO in Hong Kong, has adopted a platform structure using asset-focused subsidiaries, and expanded beyond oncology through Visara and the in-licensed ophthalmology asset VIS-101, while also acquiring Bridge Health to deepen its CLDN18.2 bispecific pipeline centered on lead asset givastomig.